Please login to the form below
Adcetris
This page shows the latest Adcetris news and features for those working in and with pharma, biotech and healthcare.
Keytruda hits primary endpoint in confirmatory lymphoma trial
The trial compared Keytruda to Seattle Genetic’s antibody-drug conjugate Adcetris – a standard treatment for relapsed and refractory lymphoma. ... Merck’s drug beat Adcetris in terms of progression-free survival (PFS), according to an interim
Latest news
-
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
Padcev is Seattle's second marketed drug after its lymphoma therapy Adcetris (brentuximab vedotin), which is expanding its business into the solid tumour category.
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Approval comes well ahead of the FDA’s action date of 15 March, and gives ADC specialist Seattle its second marketed product after lymphoma therapy Adcetris (brentuximab vedotin), expanding its business ... That would drive a sizeable step up in
-
AZ nabs US approval for new leukaemia drug Lumoxiti
Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
-
Seattle Genetics claims key US approval for Adcetris
did not achieve a complete response, with Adcetris reducing that measure by 23% compared to the control group. ... Crucially, Adcetris avoids the use of the chemotherapy drug bleomycin, which can be associated with severe and unpredictable toxicity.
-
Takeda bags EU approval for Adcetris in lymphoma
months on Adcetris, as well as improvements in median progression-free survival (PFS) and overall response rate, and symptom burden. ... The approval of Adcetris in this setting brings a much needed, effective treatment option to patients living with CTCL
More from news
Approximately 5 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
In its 2019 reviews of Pfizer’s Vizimpro and Takeda’s Adcetris, NICE noted that EQ-5D “may not be sensitive to skin-related diseases” and may fail to fully capture ... Takeda, for example, used EQ- 5D in its Adcetris programme despite doubts
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Pharma deals during April 2013
This passion has seemingly been ignited further by the recent FDA approvals of Kadcyla (Genentech/ ImmunoGen) and Adcetris (Seattle Genetics) both following impressive clinic trials in HER2 breast cancer and lymphoma,
-
Interview: Trevor Smith, Takeda
Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
